At the JP Morgan Healthcare Conference in San Francisco, Medtronic executives confirmed the company holds over $10 billion in available liquidity and an undrawn $5 billion revolving credit facility, positioning it to pursue multiple acquisitions over the next 12–18 months. Senior management emphasized that this financial flexibility comes after reducing net debt by $2.4 billion year-over-year and generating $4.1 billion in free cash flow during fiscal 2025. The company is targeting bolt-on deals in its Cardiovascular and Neuroscience businesses, where it sees opportunities to integrate complementary technologies and expand geographic reach in emerging markets.

Medtronic has entered a strategic collaboration with Precision Neuroscience to co-develop an integrated neurosurgical platform combining Precision’s Layer 7 cortical interface and Medtronic’s StealthStation surgical navigation system. The joint solution will deliver real-time functional mapping alongside high-resolution 3D structural imaging, addressing an unmet need in intraoperative decision-making. The companies plan to initiate a European pilot study involving 30 clinical sites in Q4 2026 and aim for a commercial launch in major markets by late 2028, leveraging Medtronic’s established Cranial & Spinal Technologies sales infrastructure.

Medtronic’s Diabetes unit received FDA 510(k) clearance for the MiniMed Go™ Smart Multiple Daily Injection system, which integrates the InPen™ smart insulin pen with Abbott’s Instinct continuous glucose sensor through the new MiniMed Go™ mobile app. Clinical data from 1,852 type 1 diabetes users showed Time in Range improvements from 55.7% to 67.2% when users responded to over 75% of missed-dose alerts within one hour. The system is cleared for children aged 2–6 under caregiver supervision and for individuals aged 7 and above, with commercial rollout planned in the U.S. this spring and evaluation of additional sensor compatibility under regulatory review.